This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The investigators in this study enrolled families with at least one child 5–17 years old before the 1998–99 influenza season at 15 study centers in the UK, Canada and Finland. When an influenza-like illness developed in one family member, the family was randomly assigned to receive placebo or inhaled zanamivir (Relenza), a potent and selective inhibitor of influenza A and B virus neuraminidases. The index family member received placebo or drug (10 mg BID) for 5 days, and other family members …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.